Skip to main content

ASH Highlights

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Lymphoma

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Immunotherapy

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome

Meeting Highlights

ASH Highlights, Leukemia, Novel Pharmaceuticals

Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL

Meeting Highlights

ASH Highlights, Leukemia

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Meeting Highlights

ASH Highlights, Leukemia

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

Meeting Highlights

ASH Highlights, Leukemia

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Meeting Highlights

ASH Highlights, Lymphoma, Novel Pharmaceuticals

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

ASH Highlights, Immunotherapy, Lymphoma

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Meeting Highlights

ASH Highlights, Novel Pharmaceuticals, Myelofibrosis

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

2
3
4
5
6
7

Page 5 of 7
Results 41 - 50 of 70